Results 151 to 160 of about 5,691,277 (301)

Medical cannabis Q&A [PDF]

Canadian Pharmacists Journal / Revue des Pharmaciens du Canada, 2017
openaire   +2 more sources

Commentary on Borodovsky et al.: Enhancing research on THC quantification—Consumer awareness through accurate labelling

Addiction, Volume 120, Issue 4, Page 686-687, April 2025.
Rachel Lees Thorne, Tom P. Freeman
wiley   +1 more source

Associations of cannabis use, tobacco use and co‐use with brain volume: A systematic review and meta‐analysis

Addiction, EarlyView.
Abstract Background and aims Cannabis is the most widely used illicit drug worldwide and is often co‐used with tobacco, the leading cause of preventable death. Although cannabis and tobacco have distinct neurobiological actions, their associations with brain volumes are unclear.
Katherine Sawyer, Tom P. Freeman, Martine Skumlien, Esther Walton, Thomas Lancaster, Jorien L. Treur, Valentina Lorenzetti, Anna K. M. Blackwell, Chloe Burke, Richie J. Carr, Constantinos Constantinides, Maisie Cox, Sarah Dance, Shadi Daryan, Sorcha Hamilton, Tom Jenkins, Gemma M. J. Taylor   +16 more
wiley   +1 more source

HSE will reimburse cost of Ava Twomey’s medical cannabis.

, 2018
....Mr Harris previously said the legal issues involved in developing a reimbursement process for cannabis-based products for medicinal use were being examined.
McMahon, Aine
core  

Proportions and correlates of high‐risk cannabis use in Australia—A cross‐sectional analysis of the 2022–2023 National Drug Strategy Household Survey

Addiction, EarlyView.
Abstract Background and aim Cannabis use is prevalent in Australia, however, limited research has explored the levels of high‐risk cannabis use within nationally representative samples. This study aimed to address this gap by examining the proportion of individuals meeting criteria for high‐risk cannabis use and identifying its correlates in a ...
Janni Leung, Daniel Stjepanović, Gary Chung Kai Chan, Wayne Denis Hall, Danielle Dawson   +4 more
wiley   +1 more source

Comparative effectiveness, safety and acceptability of pharmacological and psychosocial interventions for the treatment of cannabis use disorder: A network meta‐analysis

Addiction, EarlyView.
Abstract Aim Our primary aim was to conduct a network meta‐analysis (NMA) for the effectiveness, safety and acceptability of all psychosocial interventions and all pharmacotherapies for cannabis use disorder (CUD). Methods We conducted a NMA of studies identified from two completed systematic reviews examining the effectiveness, safety and ...
Monika Halicka, Francesca Spiga, Tom P. Freeman, Suzanne Nielsen, Jelena Savović, Julian P. T. Higgins, Deborah M. Caldwell   +6 more
wiley   +1 more source

Indications for Medical Cannabis and Their Alignment With US-Wide Disease Prevalences in the US' Largest Medical Cannabis Program: Cross-Sectional Study. [PDF]

JMIR Public Health Surveill
Jugl S, Smolinski NE, Aydoğan TMI, Winterstein AG.   +3 more
europepmc   +1 more source

New Jersey: Approve Cannabis Home Grow for Medical Patients

Within New Jersey’s legal Cannabis market, we have major disparities between recreational adult-use cannabis and medical cannabis. Since New Jersey has legalized adult-use cannabis, the Medical Cannabis patients' access and affordability have slowly ...
Vincent Digioia-Laird
core  

Identification of cannabis use disorder using the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM‐5) versus DSM‐5‐proxy measures: Differences by socio‐demographic characteristics

Addiction, EarlyView.
Abstract Background and Aims Cannabis use disorder (CUD) is a pressing public health concern in the United States, and understanding trends in prevalence requires considerations of how changes in measurement influence identification of CUD. Starting in 2021, the National Survey on Drug Use and Health (NSDUH) assessed CUD using all 11 Diagnostic and ...
Evan L. Eschliman, Erin M. Annunziato, Nicole D. Fitzgerald, Pia M. Mauro   +3 more
wiley   +1 more source

UK Medical Cannabis Registry: A Two-Year Prospective Observational Cohort Study of Clinical Outcomes in Insomnia. [PDF]

Neuropsychopharmacol Rep
Koye A, Erridge S, Clarke E, McLachlan K, Coomber R, Rucker JJ, Weatherall MW, Sodergren MH.   +7 more
europepmc   +1 more source